Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib’s ability to produce durable remissions in patients, acquired resistance can develop, mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Reiff, Sean D., Muhowski, Elizabeth M., Guinn, Daphne, Lehman, Amy, Fabian, Catherine A., Cheney, Carolyn, Mantel, Rose, Smith, Lisa, Johnson, Amy J., Young, Wendy B., Johnson, Adam R., Liu, Lichuan, Byrd, John C., Woyach, Jennifer A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128087/
https://ncbi.nlm.nih.gov/pubmed/30018078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-10-809020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados